Free Trial

ARS Pharmaceuticals (SPRY) SEC Filings & 10K Form

ARS Pharmaceuticals logo
$11.12 -0.50 (-4.30%)
Closing price 09/2/2025 04:00 PM Eastern
Extended Trading
$11.38 +0.27 (+2.38%)
As of 09/2/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent ARS Pharmaceuticals SEC Filings

DateFilerForm TypeView
08/27/2025
8:45 PM
ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/22/2025
3:30 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Scott Kathleen D. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/22/2025
3:30 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/21/2025
4:36 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/21/2025
3:18 PM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Scott Kathleen D. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/21/2025
10:20 AM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Lowenthal Richard E (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/19/2025
9:22 AM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Tanimoto Sarina (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/13/2025
6:02 AM
ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/13/2025
6:03 AM
ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/01/2025
5:06 PM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Flynn James E (Filed by)
Form SCHEDULE 13D/A
07/22/2025
6:38 PM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Flynn James E (Filed by)
Form SCHEDULE 13D/A
07/02/2025
7:24 AM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Flynn James E (Filed by)
Form SCHEDULE 13D/A
07/01/2025
3:42 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
DEERFIELD MANAGEMENT COMPANY, L.P. (0001009258) (Reporting)
Deerfield Mgmt III, L.P. (Reporting)
Deerfield Mgmt IV, L.P. (Reporting)
Deerfield Private Design Fund III, L.P. (Reporting)
Deerfield Private Design Fund IV, L.P. (Reporting)
Flynn James E (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2025
4:21 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Kolchinsky Peter (Reporting)
RA Capital Healthcare Fund LP (Reporting)
RA CAPITAL MANAGEMENT, L.P. (Reporting)
RA Capital Nexus Fund II, L.P. (Reporting)
Shah Rajeev M. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2025
3:43 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Dadoo Rajeev (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2025
3:30 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Shawver Laura (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2025
3:30 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
SCHNEIDER PHILLIP M (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2025
3:30 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
SAUNDERS BRENT L (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2025
3:30 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Thompson Peter A. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2025
3:30 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Islam Saqib (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2025
3:30 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Kelly Michael (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/27/2025
3:30 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Shah Pratik (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/26/2025
3:15 PM
ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/20/2025
5:38 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Karas Eric (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/18/2025
3:51 PM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Karas Eric (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/20/2025
4:24 PM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Scott Kathleen D. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/20/2025
3:48 PM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
SAUNDERS BRENT L (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/20/2025
3:50 PM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Fitzpatrick Alexander A (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/14/2025
6:01 AM
ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/14/2025
6:03 AM
ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/02/2025
7:05 AM
ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/08/2025
3:45 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Shawver Laura (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/07/2025
1:26 PM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Shawver Laura (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/24/2025
6:57 PM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Flynn James E (Filed by)
Form SCHEDULE 13D/A
03/21/2025
5:30 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Karas Eric (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/20/2025
3:03 PM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Karas Eric (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/20/2025
3:05 PM
ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/20/2025
6:02 AM
ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/20/2025
6:04 AM
ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/07/2025
4:12 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Shawver Laura (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2025
4:18 PM
ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
Washington prepares for war (Ad)

While the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much bigger here at home. Emergency powers are being invoked, trillions are being mobilized, and the scale rivals anything we’ve seen since WWII. According to Porter Stansberry and Jeff Brown, a new economic arms race is already underway — one that could reshape markets, redirect capital, and impact billions of lives. They’ve just released an urgent briefing that explains what’s really happening behind the scenes, and which companies are positioned to benefit most.tc pixel

Click here now to watch the urgent wartime exposé
03/05/2025
4:19 PM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Shawver Laura (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/04/2025
3:35 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Shawver Laura (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/03/2025
11:06 AM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Shawver Laura (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/31/2025
4:21 PM
ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
Form S-3ASR
01/13/2025
7:08 AM
ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/07/2025
5:24 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Shawver Laura (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2025
3:36 PM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Shawver Laura (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/19/2024
3:20 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2024
3:20 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/13/2024
6:52 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Dorsey Brian (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/13/2024
6:53 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Chakma Justin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/13/2024
4:24 PM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/12/2024
4:41 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Chakma Justin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/12/2024
4:02 PM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/11/2024
5:30 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2024
5:30 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/11/2024
4:31 PM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Dorsey Brian (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/10/2024
3:48 PM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/10/2024
10:15 AM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Lowenthal Richard E (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/09/2024
4:43 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/09/2024
4:25 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/09/2024
11:38 AM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Shawver Laura (Reporting)
Form 144/A
12/06/2024
6:15 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Chakma Justin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/06/2024
4:30 PM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/05/2024
4:06 PM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/03/2024
4:25 PM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/02/2024
6:01 PM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/02/2024
5:22 PM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Shawver Laura (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/02/2024
3:42 PM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Karas Eric (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/27/2024
3:11 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Chakma Justin (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/21/2024
3:30 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/21/2024
3:30 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/15/2024
2:21 PM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Chakma Justin (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/13/2024
7:16 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
DEERFIELD MANAGEMENT COMPANY, L.P. (0001009258) (Reporting)
Deerfield Mgmt III, L.P. (Reporting)
Deerfield Mgmt IV, L.P. (Reporting)
Deerfield Private Design Fund III, L.P. (Reporting)
Deerfield Private Design Fund IV, L.P. (Reporting)
Flynn James E (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/13/2024
6:02 AM
ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/13/2024
6:00 AM
ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/17/2024
3:30 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/17/2024
3:30 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/17/2024
3:30 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Scott Kathleen D. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2024
3:01 PM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Scott Kathleen D. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/15/2024
10:28 AM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Tanimoto Sarina (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/15/2024
6:02 AM
ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/10/2024
3:27 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/10/2024
3:28 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/23/2024
3:15 PM
ARS Pharmaceuticals, Inc. (Filer)
ARS Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/19/2024
3:26 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/19/2024
3:29 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/19/2024
3:30 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Karas Eric (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/18/2024
3:06 PM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Karas Eric (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/12/2024
3:24 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Lowenthal Richard E (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
Washington prepares for war (Ad)

While the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much bigger here at home. Emergency powers are being invoked, trillions are being mobilized, and the scale rivals anything we’ve seen since WWII. According to Porter Stansberry and Jeff Brown, a new economic arms race is already underway — one that could reshape markets, redirect capital, and impact billions of lives. They’ve just released an urgent briefing that explains what’s really happening behind the scenes, and which companies are positioned to benefit most.tc pixel

Click here now to watch the urgent wartime exposé
09/12/2024
3:25 PM
ARS Pharmaceuticals, Inc. (Issuer)
ARS Pharmaceuticals (Issuer)
Tanimoto Sarina (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/10/2024
9:31 AM
ARS Pharmaceuticals, Inc. (Subject)
ARS Pharmaceuticals (Subject)
Lowenthal Richard E (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:SPRY) was last updated on 9/3/2025 by MarketBeat.com Staff
From Our Partners